Literature DB >> 14675806

Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652.

H Blair Simpson1, Ilise Lombardo, Mark Slifstein, Henry Yiyun Huang, Dah Ren Hwang, Anissa Abi-Dargham, Michael R Liebowitz, Marc Laruelle.   

Abstract

BACKGROUND: Serotonergic abnormalities have been hypothesized to contribute to obsessive-compulsive disorder (OCD). This study examined whether brain serotonin transporter (SERT) availability is altered in OCD using positron emission tomography (PET) and the SERT PET radiotracer [(11)C]McN 5652.
METHODS: Eleven OCD subjects, free of psychiatric medications and comorbid depression, and 11 matched healthy control subjects underwent PET scans following injection of [(11)C]McN 5652 and magnetic resonance imaging (MRI) scans. Total distribution volumes (V(T)) were derived by kinetic analysis (one tissue compartment model) using the arterial input function. Two measures of SERT availability were computed: binding potential (BP) and specific to nonspecific partition coefficient (V(3)"). Groups were compared using region of interest (ROI) analysis and voxelwise analysis of spatially normalized parametric maps; ROIs were selected based on their relatively high SERT density and included subcortical (dorsal caudate, dorsal putamen, ventral striatum, midbrain, thalamus) and limbic (hippocampus, amygdala, anterior cingulate cortex) regions.
RESULTS: No significant group differences were observed in [(11)C]McN 5652 BP or V(3)" in the ROIs. No significant group differences were detected in the voxelwise analysis of BP or V(3)" maps.
CONCLUSIONS: OCD without comorbid depression, may not be associated with major changes in SERT availability in subcortical and limbic regions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675806     DOI: 10.1016/s0006-3223(03)00544-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  22 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

2.  In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer.

Authors:  Matthew S Milak; Christine DeLorenzo; Francesca Zanderigo; Jaya Prabhakaran; J S Dileep Kumar; Vattoly J Majo; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2010-12       Impact factor: 10.057

3.  In vivo quantification of serotonin transporters using [(11)C]DASB and positron emission tomography in humans: modeling considerations.

Authors:  R Todd Ogden; Ashish Ojha; Kjell Erlandsson; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-17       Impact factor: 6.200

4.  Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.

Authors:  Helen Blair Simpson; Mark Slifstein; James Bender; Xiaoyan Xu; Elizabeth Hackett; Michael J Maher; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2011-11-01       Impact factor: 13.382

5.  Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Authors:  M Reimold; M N Smolka; A Zimmer; A Batra; A Knobel; C Solbach; A Mundt; H U Smoltczyk; D Goldman; K Mann; G Reischl; H-J Machulla; R Bares; A Heinz
Journal:  J Neural Transm (Vienna)       Date:  2007-08-22       Impact factor: 3.575

6.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

7.  Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder.

Authors:  David Pagliaccio; Rachel Middleton; Dianne Hezel; Shari Steinman; Ivar Snorrason; Marina Gershkovich; Raphael Campeas; Anthony Pinto; Page Van Meter; H Blair Simpson; Rachel Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

8.  Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET.

Authors:  Matthew S Milak; Alin J Severance; R Todd Ogden; Jaya Prabhakaran; J S Dileep Kumar; Vattoly J Majo; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

9.  Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography.

Authors:  Maria A Oquendo; Ramin S Hastings; Yung-Yu Huang; Norman Simpson; R Todd Ogden; Xian-Zhang Hu; David Goldman; Victoria Arango; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Arch Gen Psychiatry       Date:  2007-02

10.  Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).

Authors:  Katarina Stengler-Wenzke; Ulrich Müller; Matthias C Angermeyer; Osama Sabri; Swen Hesse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-08       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.